Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5395881 | 0.98 | TLR8 (0.52) | TLR8FLT3F2F10CA2 | |
| SCHEMBL7796046 | 0.95 | ALOX15 (0.47) | TLR8FLT3F2F10CA2 | |
| SCHEMBL8179634 | 0.90 | TLR8 (0.47) | TLR8FLT3F2F10CA2 | |
| SCHEMBL12370192 | 0.81 | TLR8 (0.44) | TLR8F2F10CA2ALOX15 | |
| SCHEMBL2333763 | 0.80 | CYP19A1 (0.47) | TLR8F2F10CA2ALOX15 | |
| SCHEMBL2327940 | 0.80 | TLR8 (0.43) | TLR8F2F10CA2ALOX15 | |
| SCHEMBL2326095 | 0.80 | TLR8 (0.43) | TLR8F2F10ALOX15MAPT | |
| SCHEMBL2330441 | 0.80 | ALOX15 (0.58) | TLR8FLT3F2F10ALOX15 | |
| SCHEMBL2331524 | 0.80 | KMT2A (0.55) | TLR8F2F10ALOX15MAPT | |
| SCHEMBL14552009 | 0.80 | TLR8 (0.43) | TLR8FLT3F2F10CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | claimed |
| US-20050049302-A1 | Process for the preparation of dronedarone | ISP INVESTMENTS LLC | 2005-03-03 | — | — | US | claimed |
| US-6828448-B2 | 2-butyl-5-(methanesulfonamido)benzofuran; preparation of dronedarone | SANOFI-SYNTHELABO (FR) | 2004-12-07 | — | — | US | claimed |
| EP-1343777-B1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI SYNTHELABO (FR) | 2004-05-06 | — | — | EP | claimed |
| US-20040048921-A1 | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate | SANOFI (FR) | 2004-03-11 | — | — | US | claimed |
| EP-1343777-A1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI-SYNTHELABO (FR) | 2003-09-17 | — | — | EP | claimed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2002048132-A1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI-SYNTHELABO (FR) | 2002-06-20 | — | — | WO | claimed |
| CN-109384754-B | Preparation method of dronedarone hydrochloride | 新发药业有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-9708281-B2 | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent | SANOFI (FR) | 2017-07-18 | — | — | US | disclosed |
| US-9708281-B2 | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent | SANOFI (FR) | 2017-07-18 | — | — | US | disclosed |
| US-9708281-B2 | Process for preparation of dronedarone by the use of dibutylaminopropanol reagent | SANOFI (FR) | 2017-07-18 | — | — | US | disclosed |
| US-9701654-B2 | Process for preparation of dronedarone by removal of hydroxyl group | SANOFI (FR) | 2017-07-11 | — | — | US | disclosed |
| US-9701654-B2 | Process for preparation of dronedarone by removal of hydroxyl group | SANOFI (FR) | 2017-07-11 | — | — | US | disclosed |
| EP-1343777-A1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI-SYNTHELABO (FR) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003048145-A2 | METHOD FOR PREPARING AN AMINOBENZOFURAN COMPOUND | RHODIA CHIMIE (FR) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002048132-A1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI-SYNTHELABO (FR) | 2002-06-20 | — | — | WO | disclosed |
| US-5223510-A | ALKYLAMINOALKYL DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1993-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048921-A1 | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate | CYP2F1, DHPS, CYP2D6 | TLR8 4183/4885FLT3 3442/4885F2 1054/4885 |
| US-20050049302-A1 | Process for the preparation of dronedarone | CACNA1C, CACNA1A, KCNH1 | TLR8 4345/4885FLT3 4471/4885F2 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.